Esperion stock hits 52-week low at $1.55 amid market challenges

Esperion Therapeutics Inc. (NASDAQ:ESPR) stock has reached a new 52-week low, touching down at $1.55 USD, signaling a tough period for the biopharmaceutical company. According to InvestingPro data, the stock has fallen over 10% in just the past week, with a market capitalization now at $310.62 million. This latest price point reflects a significant downturn from previous valuations, as investors show concern over the company’s performance and market position. Despite impressive revenue growth of 185.66% over the last twelve months, the company operates with a substantial debt burden of $591.21 million. Over the past year, Esperion’s stock has experienced a notable decline, with a 1-year change showing a decrease of -23.17%. This downward trend highlights the challenges faced by the company in a competitive industry, as well as the potential impact of broader market forces affecting investor confidence. InvestingPro subscribers can access 6 additional key insights about ESPR’s financial health and market position in the comprehensive Pro Research Report.

In other recent news, Esperion Therapeutics reported a significant revenue increase of 114% year-over-year for the fourth quarter of 2024, reaching $69.1 million, which surpassed the forecast of $63.45 million. This growth was driven by a 52% increase in U.S. net product revenue and a 227% surge in collaboration revenue. Despite this success, U.S. net product sales of $31.6 million fell short of JMP’s prediction of $35 million and the consensus estimate of $34.5 million. The company’s earnings per share (EPS) were reported at -$0.11, better than the anticipated -$0.14. JMP analysts maintained their Market Outperform rating and $4.00 price target for Esperion, citing the company’s global growth potential and ongoing U.S. commercialization efforts. Esperion ended the fiscal year 2024 with approximately $145 million in cash, positioning it well for future investments. The company also noted an 8% rise in new-to-brand prescriptions, with more than 25,000 healthcare professionals prescribing its products in the fourth quarter. Looking ahead, Esperion plans to expand its market presence in Japan, Israel, and Canada, with a focus on developing triple combination products for LDL cholesterol reduction.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.